Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma

Leukemia and Lymphoma

Volumn 57, Issue 11, 2016, Pages 2510-2515

  Barley, Kevin ^a   He, Wei ^a   Agarwal, Shradha ^a   Jagannath, Sundar ^a   Chari, Ajai ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Lenalidomide; myeloma; pomalidomide; rash; thalidomide

Indexed keywords

ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIHISTAMINIC AGENT; CORTICOSTEROID; COTRIMOXAZOLE; DEXAMETHASONE; LENALIDOMIDE; METHYLPREDNISOLONE; POMALIDOMIDE; PREDNISONE; STEROID; THALIDOMIDE; IMMUNOLOGIC FACTOR;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RECHALLENGE; DRUG REEXPOSURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERVENTION STUDY; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEASLES LIKE RASH; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NATIONAL CANCER INSTITUTE CANCER THERAPY EVALUATION PROGRAM COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENT CRITERIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; STEVENS JOHNSON SYNDROME; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT OUTCOME; URTICARIA; ANALOGS AND DERIVATIVES; COMPLICATION; DISEASE MANAGEMENT; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; DISEASE MANAGEMENT; EXANTHEMA; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84962567119     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2016.1151507     Document Type: Article

References (24)

1. V.C.Hall, R.A.El-Azhary, S.Bouwhuis, et al. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol. 2003;48:548–552.
2. B.Nardone, S.Wu, B.C.Garden, et al. Risk of rash associated with lenalidomide in cancer patients:a systematic review of the literature and meta-analysis. Clin Lymphoma Myeloma Leuk. 2013;13:424–429.
3. A.Patrizi, M.Venturi, E.Dika, et al. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma:new drugs, old side effects. Cutan Ocul Toxicol. 2013;33:1–2
4. H.P.Sviggum, M.D.Davis, S.V.Rajkumar, et al. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol. 2006;142:1298–1302.
5. A.Larocca, V.Montefusco, S.Bringhen, et al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma:a multicenter phase 1/2 open-label study. Blood. 2013;122:2799–2806.
6. C.P.Castaneda, N.A.Brandenburg, R.Bwire, et al. Erythema multiforme/Stevens–Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J Clin Oncol. 2009;27:156–157.
7. C.Michot, B.Guillot, O.Dereure Lenalidomide-induced acute acneiform folliculitis of the head and neck:not only the anti-EGF receptor agents. Dermatology. 2010;220:49–50.
8. M.G.Perez-Paredes, M.A.Rodriguez-Prieto, I.Ruiz-Gonzalez, et al. Lenalidomide-induced photosensitivity. Photodermatol Photoimmunol Photomed. 2013;29:334–336
9. N.D.Yildirim, M.Ayer, R.D.Kucukkaya, et al. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. Jpn J Clin Oncol. 2007;37:704–707.
10. P.Demoly, N.F.Adkinson, K.Brockow, et al. International consensus on drug allergy. Allergy. 2014;69:420–437.
11. D.A.Ostrov, B.J.Grant, Y.A.Pompeu, et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire. Proc Natl Acad Sci USA. 2012;109:9959–9964.
12. G.Penna, A.Allegra, G.Romeo, et al. Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602. Acta Oncol. 2012;51:944–947.
13. J.Shortt, A.K.Hsu, R.W.Johnstone Thalidomide-analogue biology:immunological, molecular and epigenetic targets in cancer therapy. Oncogene. 2013;32:4191–4202.
14. G.Lu, R.E.Middleton, H.Sun, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343:305–309.
15. J.Kronke, N.D.Udeshi, A.Narla, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343:301–305.
16. M.J.Lee, P.Wickner, L.Fanning, et al. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma. Br J Haematol. 2014;167:127–131.
17. Y.Balagula, A.Rosen, B.H.Tan, et al. Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. Cancer. 2012;118:5078–5083.
18. J.R.Brahmer, S.S.Tykodi, L.Q.Chow, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465.
19. K.Luptakova, J.Rosenblatt, B.Glotzbecker, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013;62:39–49.
20. A.G.Ramsay Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 2013;162:313–325.
21. H.B.Liu, Y.Wu, T.F.Lv, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer:a systematic review and meta-analysis. PLoS One. 2013;8:e55128.
22. Revlimid(R) [package insert]. Summit, NJ:Celgene Corporation; February, 2015; [cited 2015 Dec 28]. Available from:http://www.revlimid.com/wp-content/uploads/full-prescribing-information.pdf.
23. Thalomid(R) [package insert]. Summit, NJ:Celgene Corporation; August, 2015; [cited 2015 Dec 28]. Available from:http://www.thalomid.com/pdf/Thalomid_PI.pdf.
24. Pomalyst(R) [package insert]. Summit, NJ:Celgene Corporation; April, 2015; [cited 2015 Dec 28]. Available from:http://www.pomalyst.com/wp-content/uploads/prescribing_information.pdf.